Serabelisib - Takeda Oncology

Next Previous
Drug Profile

Serabelisib - Takeda Oncology

Alternative Names: INK-1117; MLN-1117; TAK-117

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intellikine
  • Developer Baylor Research Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); Takeda; Takeda Oncology
  • Class Antineoplastics; Imidazoles; Morpholines; Pyridines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Endometrial cancer; Renal cell carcinoma
  • Phase I Solid tumours
  • Discontinued Gastric cancer; Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 30 Jan 2018 Chemical structure information added
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top